F.Haldor HansenT.VinbergM.KessingL
Case Study #3: Athletic Performance Optimization Patient: 38-year-old male competitive age-group triathlete Chief Complaints: Declining recovery between training sessions, persistent low-grade injuries, inability to hit previous power numbers despite consistent training Baseline Assessment: IGF-1: 168 ng/mL (suboptimal for training load) Testosterone: 512 ng/dL (adequate but not optimal for performance goals) hs-CRP: 2.1 mg/L (chronic low-grade inflammation) Ferritin: 32 ng/mL (suboptimal for endurance athlete) Training metrics: 7-day recovery time after hard sessions (goal: 2-3 days) Treatment Protocol: Foundation: Address iron deficiency with supplementation, optimize nutrition timing around training Hormone optimization: Testosterone enanthate to achieve 850-950 ng/dL range Peptide therapy: Sermorelin 400 mcg nightly, 6 nights/week (timed around training schedule) Supporting interventions: Sleep optimization protocol, targeted anti-inflammatory nutrition 16-Week Results: IGF-1: 284 ng/mL (+69%) Recovery time: 2-3 days for hard sessions (71% improvement) FTP (functional threshold power): +18 watts Body composition: -2.1% body fat, +1.9 kg lean mass hs-CRP: 0.6 mg/L (normalized) Race results: Two age-group podiums in half-iron distance races Patient Report: The recovery improvement is dramatic
This could be because the Vitamin B12 is helping to regulate your cells and their metabolic cycles, and it could be because you use more energy during the day, thus napping less and finding your body ready for sleep at night
Maintenance doses are typically 1 mg every 2-3 months for life High-dose oral therapy (1000-2000 micrograms daily) may be effective in selected patients with pernicious anaemia under clinical supervision, as passive diffusion can compensate for absent intrinsic factor, though this is not routine first-line treatment in the UK The water-soluble nature of B12 means that high-dose supplementation carries minimal risk of toxicity , making it a safe option for individuals with confirmed or suspected deficiency
FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding On September 29, 2023, updates were made to the list of bulk drug substances nominated for use under Section 503A
Remove Air Bubbles After drawing medication, tap the syringe gently to move air bubbles to the top, then push them out carefully
